TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Hemoglobin A1C of ≥7.5% and ≤10.5%~* Currently taking a stable dose of metformin (at least 1500 mg/day) and either glimepiride (at least 2 mg/day) or gliclazide (at least 50% of maximum registered dose) for at least 10 weeks prior to study start~* Male, or a female who is highly unlikely to conceive~Exclusion Criteria:~* Type 1 diabetes mellitus or ketoacidosis~* Taking a dipeptidyl peptidase-4 (DPP-4) inhibitor (such as sitagliptin) or a glucagon-like peptide-1 (GLP-1) mimetic (such as exenatide or liraglutide) or required insulin therapy within 12 weeks prior to study start~* On a weight loss program not in the maintenance phase or on a weight loss medication~* History of liver disease, heart failure, heart disease, stroke, high blood pressure, blood disorders, or cancer~* HIV positive~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- placebo/pioglitazone (Type: ACTIVE_COMPARATOR): Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): placebo to Sitagliptin 100 mg + pioglitazone 30 mg
- Sitagliptin (Type: EXPERIMENTAL): Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + placebo to pioglitazone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males, females, age 30, - 75 years, type 2 diabetes mellitus, treated with metformin ≥1.0 g/day, at a stable dose for at least 3 months, BMI 25 - 40 kg/m2, HbA1C ≥7.0% and \<9.0%.~Exclusion Criteria:~* Type 1 diabetes, pregnancy, lactation, women of childbearing potential, treatment with other antidiabetic agents than metformin, history of metabolic acidosis, hemoglobinopathy or hemolytic anemia, clinically significant medical abnormalities.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study for Patients With Complicated Skin and Skin Structure Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Complicated skin and skin structure infection, presumed or proven to be caused by gram-positive pathogen(s).~* Patients, ages 18 years and older, must not be below normal body weight or morbidly obese.~* Female patients must not be pregnant at time of enrollment and must agree to a reliable method of birth control during the study and for 6 months following the last dose of study drug.~Exclusion Criteria:~Patients:~* with a condition which would prevent performing protocol safety and efficacy assessments.~* who have received antibiotics for more than 24 hours within the last 3 days.~* with an infection involving deep tissues or unlikely to be caused by gram positive bacteria~* who are nursing and will not stop nursing for at least 6 months~* with a prior allergic reaction to glycopeptides (e.g. vancomycin)~* with any of the following:~  1. toxic shock syndrome or toxic-like syndrome~ 2. presumed or proven infection caused by Clostridium species~ 3. bone infections~ 4. ischemic or gangrenous ulcers or wounds~ 5. infections caused only by gram-negative bacteria~ 6. infection of an artificial joint that cannot be removed~ 7. infection of the scrotum, perineum or perianal region~ 8. infection of a severe burn wound~ 9. severe ear infection involving bone and/or cartilage~ 10. infection following injury in water possibly containing Vibrio species or following a history of eating raw oysters within 1 week prior to disease onset

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Discharge Medication Counseling in Hospitalized Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Caregivers of children up to 6 years old who are hospitalized on a general inpatient hospital medicine teams~* Caregivers must speak English or Spanish~* Participants' children must be discharged home on new scheduled liquid medication for minimum 3 days.~Exclusion Criteria:~* Medication will be administered by home health nurse~* Child is in state/protected custody~* Medication prescription is prescribed to pharmacy other than hospital outpatient pharmacy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): Participants in the usual care group will receive standard-of-care discharge communications per unit routine, including counseling regarding prescribed medications and post-discharge instructions, return precautions, and follow-up appointments by the pediatric nursing staff.
- Intervention (Type: EXPERIMENTAL): Participants in the intervention group will receive supplementary medication discharge instructions in addition to the standard communications. They will receive instructions on how to submit information and complete study surveys securely through their cellphones during their child's home treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Heart Failure with Preserved Ejection Fraction (HFpEF)~* Normal left ventricular ejection fraction (≥50%)~* Elevated Left Ventricular filling pressures at cardiac catheterization (defined as resting Pulmonary Capillary Wedge Pressure\>15 mmHg and/or ≥25 mmHg during exercise).~Exclusion Criteria:~* Prior albuterol therapy (within previous 48 hours)~* Current long acting inhaled beta agonist use~* Significant hypokalemia (\<3meq/L)~* Significant valvular disease (\>moderate left-sided regurgitation, \>mild stenosis)~* High output heart failure~* Severe pulmonary disease~* Unstable coronary disease~* Constrictive pericarditis~* Restrictive cardiomyopathy~* Hypertrophic cardiomyopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled albuterol (Type: EXPERIMENTAL): 2.5 mg inhaled albuterol through a high efficiency nebulizer -single dose
- Inhaled saline placebo (Type: PLACEBO_COMPARATOR): Inhaled saline through a high efficiency nebulizer -single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: My Diabetes Care Mobile: A Usability Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes Mellitus~* Currently taking at least one medication for diabetes~* Age 21 or over~* Able to speak and read in English~* Reliable access to a smartphone or tablet with internet access~* Active VUMC patient web portal (known as My Health At Vanderbilt) account~Exclusion Criteria:~* Residing in a long term care facility~* Medical condition that affects my memory or ability to think.~* Severe visual impairment~* Patients with unintelligible speech (e.g., dysarthria)~* Currently participating in another diabetes-related research study

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- My Diabetes Care Mobile (MDC-m) (Type: EXPERIMENTAL): Patients have access to a patient web portal embedded with the My Diabetes Care Mobile (MDC-m) intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥18 and ≤55 years of age~* Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mm Hg; diastolic blood pressure, 50-90 mm Hg; heart rate, 50-100 bpm~* Body mass index (BMI) ≥18 and ≤35 kg/sq m~* Able to provide written informed consent~Exclusion Criteria:~* Use of any medication (prescription, over-the-counter, herbal tea, or supplements) within 5 days of dosing~* Use of any investigational agent or study treatment within 30 days of Day 1~* Use of any protein or antibody-based therapeutic agents within 3 months of Screening~* Prior exposure to any SGLT inhibitor~* Use of cigarettes or any tobacco products within 6 weeks prior to Screening and while participating in the study~* History of bariatric surgery or any other gastrointestinal surgery that may induce malabsorption~* History of any major surgery within 6 months of Screening~* History of any hypersensitivity to the inactive components of LX4211~* History of renal disease or significantly abnormal kidney function tests~* History of hepatic disease or significantly abnormal liver function tests~* History of any active infection within 30 days of Day 1~* History of alcohol or substance abuse within 2 years prior to Day 1~* Positive urine glucose at Screening~* Positive pregnancy test at Screening~* Inability or difficulty swallowing whole tablets or capsules~* Unable or unwilling to communicate or cooperate with the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- LX4211 (Type: EXPERIMENTAL): 400 mg of LX4211 administered orally
- Placebo (Type: PLACEBO_COMPARATOR): Nonidentical placebo administered orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple Dose ASM8 in Mild Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Part 1: Men and women 18 to 65 years of age; generally good health; mild to moderate, stable, allergic asthma as defined by ATS criteria (1); history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline ≥70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.~Part 2: Methacholine challenge at baseline (PC20 ≤16 mg/mL); positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway bronchoconstriction.~Exclusion Criteria:~* Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting β2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Tennis Elbow With Botulinum Toxin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years and up~* Pain at the lateral side of the elbow~* Pain at the lateral epicondyle during resisted dorsiflexion of the wrist with the elbow in full extension~* Pain for longer than 3 months~Exclusion Criteria:~* Previous operations (including previous steroid injections for the disorder)~* Nerve entrapment~* Pregnancy and while breast-feeding~* Presence of systemic neuromuscular disorders such as myasthenia gravis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has Type 2 Diabetes~* Patient is between the ages of 30-65 years~* Patient is not on an antihyperglycemic agent (AHA) (glycosylated hemoglobin \[A1C\] 7-10% ), or is on oral single AHA or low-dose combination therapy (A1C 6.5-9.5%).~Exclusion Criteria:~* Patient has Type 1 Diabetes~* Patient has been treated with sitagliptin, vildagliptin, or other similar drugs or has been treated with exenatide in the past 3 months~* Patient has taken insulin within the past 3 months

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): sitagliptin 100 mg
- 2 (Type: EXPERIMENTAL): sitagliptin 200 mg
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating female 18 years of age or older.~* Have a definite clinical diagnosis of stable plaque psoriasis involving ≥ 10% of the body surface area (BSA).~* Have a combined total lesion severity score (TLSS) of ≥ 7 for the Target Lesion.~* Have a plaque elevation score ≥ 3 of (moderate) for the Target Lesion.~* The Target Lesion must have an area of at least 5 cm².~* Have a Physicians Global Assessment (PGA) score of 3 (moderate) or 4 (severe) at baseline for the overall disease severity.~Exclusion Criteria:~* Patient has current diagnosis of other types of psoriasis other than stable plaque psoriasis (i.e. acute, guttate, erythrodermic, exfoliative or pustular psoriasis) or has psoriasis of any kind of the face or scalp that will require active treatment during the study. Nonprescription antipsoriatic shampoos will be allowed during the study when applied solely to the scalp.~* Patient has a history of psoriasis that has been unresponsive to topical corticosteroid therapy.~* In the Investigator's opinion, the patient has other dermatological conditions, such as atopic or contact dermatitis, that may interfere with the clinical assessments of the signs and symptoms of psoriasis.~* Patient has a history of allergy or sensitivity to corticosteroids or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the patient or the results of the study.~* Patient has been treated within 12 weeks (or five half lives, whichever is less) prior to the first dose of study drug with any biological therapies for psoriasis.~* Patient has received any systemic steroids within 4 weeks of the first dose of the study drug. The use of inhaled or intranasal corticosteroids is acceptable as long as usage has been stable for at least 2 weeks prior to the first dose of study drug and will be continued during the study.~* Patients who have used any topical antipsoriatic agents of any kind or any topical corticosteroids for any reason within 2 weeks prior to first use of study drug. Nonprescription antipsoriatic shampoos used only on the scalp will be allowed during the study.~* Receipt of any drug as part of a research study within 30 days prior to first dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- active product (Type: EXPERIMENTAL): Desoximetasone Spray 0.25%
- placebo comparator (Type: PLACEBO_COMPARATOR): vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH)~* Diagnosis of Coronary Artery Disease (CAD)~* Stable lipid-lowering therapy for 12 weeks~* On maximally tolerated statin therapy with at least 1 statin at a dose greater than zero, per Investigator judgment~* Stable low-fat diet for 8 weeks~* Stable weight for 6 weeks~Exclusion Criteria:~* Significant health problems in recent past including heart attack, stroke, coronary syndrome, unstable angina, heart failure, significant arrhythmia, orthostatic hypotension, uncontrolled hypertension, blood disorders, liver disease, cancer, or digestive problems~* Receiving apheresis treatment or last apheresis treatment within 8 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mipomersen (Type: EXPERIMENTAL): Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a placebo subcutaneous injection once a week for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Kidney transplant recipient~* \> 6 months posttransplant~* Serum creatinine \< 1.6 mg/dL~* Currently taking a stable dose of tacrolims~Exclusion Criteria:~* On medications known to interact with tacrolimus or ketoconazole~* Multi-organ transplant recipient~* Serum creatinine \>1.5 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus + Ketoconazole, Then Tacrolimus alone (Type: EXPERIMENTAL): Participants first received tacrolimus in combination with with ketoconazole. After a 1-2 week washout they received tacrolimus alone.
- Tacrolimus alone, Then Tacrolimus + Ketoconazole (Type: EXPERIMENTAL): The participants first received tacrolimus alone. After a 1-2 week washout period they received tacrolimus in combination with ketoconazole.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female above 18 years;~2. Subject with clinical diagnosis of mild AK on the face or the scalp with or without clinical diagnosis of moderate AK on the target areas (TAs);~Exclusion Criteria:~1. Subject with clinical diagnosis of at least one severe AK on TAs~2. Subject with clinical diagnosis of other skin disease (including non-melanoma skin cancer) on the TAs;~3. Subject with pigmented AK on the TAs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metvix and daylight (Type: EXPERIMENTAL): None
- Metvix and lamp (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete